Meta-analysisindependent cross-checkfull text checked I-INTB-19 in-depth review
Do statins cause muscle pain?
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
Overview
Cholesterol Treatment Trialists' Collaboration. Lancet 2022 · PMID 36049498 · DOI 10.1016/S0140-6736(22)01545-8
Statins cause a small excess of mild muscle pain, mostly in year 1; most muscle complaints are not caused by the statin.
Does the study support the specific claim? Partly · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Quantify statin muscle effects
- How was the study done?
IPD meta-analysis
- How many people, animals or samples were studied?
154,664 participants in 23 double-blind trials
- What was actually found?
Small excess, mainly year 1
- How large was the observed effect?
RR 1.03; 11/1000 person-years
- What do the results mean in everyday life?
Muscle aches on statins are usually not from the statin, but a few are.
- What are the study's limitations?
Different trials recorded muscle symptoms differently; creatine kinase rarely measured
- What does it say about Elawady's specific claim?
Acknowledges a real side effect; contradicts banning statins.
- Do the results apply to Germany and Europe?
High
Scientific in-depth review
1. Full reference
- Authors
- Cholesterol Treatment Trialists' Collaboration
- Journal
- Lancet
- Year
- 2022
- Identifier
- PMID 36049498 DOI 10.1016/S0140-6736(22)01545-8
- Verification
- verified – PubMed efetch 2026-10-25
- Retracted
- no
- Corrections
Erratum published (PubMed ErratumIn PMID 36216002)
- Extent checked
- full text
- Conflicts of interest and funding
CTT funded by British Heart Foundation, UK MRC and Australian NHMRC; no industry grant funding to CTT (contributing trials were largely industry-funded). Some authors report institutional grants and fees from industry (Novartis, Abbott, Amgen, AstraZeneca, Pfizer, Sanofi, etc.); one author holds a licensed patent for a statin-myopathy genetic test (personal reward waived). Independent oversight committee. Publication corrected (October 2022).
2. Research question
How often do statins cause muscle pain or weakness?
3. Study design and population
- Study design
- Meta-analysis – IPD meta-analysis of 23 double-blind RCTs
- Population
Participants of 19 double-blind statin vs placebo trials (mean age 63 years, 27.9% women, 48.1% previous vascular disease, 18.5% diabetes) and 4 double-blind trials of more vs less intensive statin (all with vascular disease, mean age 62)
- Country
Multinational (CTT Collaboration; coordinated from Oxford, UK and Sydney, Australia)
- Period
Weighted median follow-up 4.3 years (placebo-controlled) and 4.9 years (intensity trials); background search Medline/CENTRAL 1990 to June 2021
- Sample size
154,664 participants: 123,940 (19 statin vs placebo trials) + 30,724 (4 more vs less intensive trials)
- Inclusion and exclusion criteria
Double-blind trials of statin vs placebo or more vs less intensive statin, >=1000 participants, scheduled mean follow-up >=2 years, unconfounded; individual adverse-event data coded to MedDRA. A few participants withdrew consent post-trial (AURORA 218, CORONA 27, JUPITER 1088); missing data <1% of adverse events.
4. Methods and endpoints
- Exposure / intervention
Statin regimens classified as low, moderate or high intensity (AHA/ACC)
- Comparator
Placebo / less intensive statin
- Endpoints
First reports of muscle pain or weakness (myalgia, limb pain, other musculoskeletal pain, cramp/spasm, fatigue/weakness), myopathy (coded), creatine kinase values
- Statistical methods
Prespecified protocol; intention-to-treat; inverse-variance-weighted log-rank (O-E) meta-analysis; direct plus indirect comparisons for high-intensity regimens; 95% CI for overall and 99% CIs for other estimates; attributable proportion 100 x (RR-1)/RR; negative binomial models for all events; Wilcoxon tests for CK.
5. Actual results
- Results
Muscle pain or weakness: 16,835 (27.1%) statin vs 16,446 (26.6%) placebo, RR 1.03 (1.01-1.06). Year 1: RR 1.07 (1.04-1.10), absolute excess 11 (6-16) per 1000 person-years, about 1 in 15 reports attributable to statin; after year 1: RR 0.99 (0.96-1.02), 0 (-2 to 1) per 1000 person-years. Low/moderate intensity RR 1.03 (1.00-1.05); high intensity RR 1.08 (1.04-1.13), year 1 1.11 (1.05-1.17), after year 1 1.05 (0.99-1.12). Higher RR in women for low/moderate regimens (1.09 vs 1.00; not confirmed in intensity trials). Myopathy 0.08% vs 0.04%, RR 1.74 (1.11-2.74), absolute excess 0.08 (0.01-0.18) per 1000 person-years; marked excess with simvastatin 80 mg (SEARCH). Median CK increase about 0.02 x ULN. No difference between statins.
- Absolute risks
Excess muscle pain or weakness 11 (6-16) per 1000 person-years in year 1, ~0 thereafter; myopathy excess 0.08 per 1000 person-years. Authors' comparison: per 1000 people with ~1 mmol/L LDL reduction for 5 years, about 11 mostly mild muscle episodes caused vs 50 (secondary prevention) or 25 (primary prevention) major vascular events prevented.
- Authors' conclusion
Statins caused a small excess of mostly mild muscle pain; >90% of muscle-symptom reports on statins were not due to the statin; risks are much lower than cardiovascular benefits.
6. Strengths
- Individual adverse-event data from large double-blind RCTs, avoiding nocebo and reporting bias of observational studies
- Prespecified protocol and outcome definitions; common MedDRA coding
- Timing, intensity, subgroup and run-in analyses; consistent relative effects across trials
7. Weaknesses
- Heterogeneous ascertainment of muscle symptoms across trials (first-year reporting 1.0% to 60.5%)
- CK measured in <6.2% of symptom reports
- Limited data on discontinuation due to muscle symptoms and on relevant comorbidities/concomitant drugs
- Trials did not systematically exclude or identify people with prior statin intolerance; mostly industry-funded trials
- Indirect comparison needed for high-intensity vs placebo
8. Risk of bias
- Orienting tool
- AMSTAR 2 (IPD meta-analysis of double-blind RCTs)
- Type of assessment
- structured assessment based on the full text by a single reviewer (no formal double review)
- Full formal assessment
- no
- Overall risk of bias
- low
- Rationale
Overall unchanged (low). Simplified single-reviewer judgement from the full text; a formal AMSTAR 2/ROBIS assessment requires two independent reviewers.
| Domain | Judgement | Rationale |
|---|---|---|
| Item 2 (critical) protocol | low | Methods and analyses prespecified in published protocol; outcome categories defined before unmasking. |
| Item 4 (critical) comprehensive search | low | CTT registry of eligible trials plus Medline/CENTRAL search; IPD obtained from all eligible double-blind trials. |
| Item 7 (critical) excluded studies | low | Eligibility clear; missing data <1% of events explained. |
| Item 9 (critical) RoB of included trials | low | Restricted to large double-blind randomised trials, analysed by ITT. |
| Item 11 (critical) meta-analytic methods | low | Standard IPD log-rank meta-analysis; direct+indirect estimates; 99% CIs for multiplicity. |
| Item 13 (critical) RoB in interpretation | low | Limitations (ascertainment heterogeneity, missing CK, intolerance exclusion) discussed. |
| Item 15 (critical) publication/reporting bias | low | All recorded adverse events obtained at individual level, not published summaries. |
| Item 16 review COI | some concerns | Public funding and independent oversight; several authors with industry ties and one with a related patent. |
Full-text review (25 October 2026): Added baseline characteristics, prespecified outcome definitions, intensity-specific and time-specific RRs, myopathy RR 1.74 (1.11-2.74) and absolute excess 0.08/1000 person-years, CK data, sex subgroup, benefit-harm comparison, funding (no industry grants to CTT) and author COIs. Bias overall unchanged (low) with itemised AMSTAR 2.
9. Assessment of the statistical interpretation
Statins cause a small, real excess of mostly mild muscle symptoms in year 1 (RR 1.07; 11 per 1000 person-years) and a small excess of rare myopathy; over 90% of muscle complaints on statins are not caused by the drug.
10. Relevance to the specific claim
Fair point: statins do cause some muscle symptoms, but rarely; contradicts a blanket ban.
11. Independent contrary findings
12. Transferability to Germany and Europe
High.
13. Overall methodological judgement
High-quality evidence that statin-related muscle harm exists but is small and mostly mild, far outweighed by cardiovascular benefit in people who need treatment.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | low |
| Precision of results | high |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Management of persistent symptoms.
15. Linked fact checks
- For six or seven years he alone has said that statins (Crestor, Ator, Lipitor) are forbidden, and that Controloc (pantoprazole) is forbidden. – Studies with mixed or unclear results